Your Source for BioScience Venture Capital Data
  • SEARCH THE OnBioVC DATABASE:

  • OnBioVC NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • Photobucket

  • FDA Registered Contract Manufacturer

New Haven Pharmaceuticals (New Haven, CT), a specialty pharmaceutical company focused on a slow release aspirin product, closed a $6.6M Series A. Participants include Connecticut Innovations and private investors.

Synovex (Boston, MA), a clinical stage biotechnology company focused on inhibiting the progression of fibrotic diseases such as arthritis, closed a $3.5M Series C financing. Participants were not identified.

Neurovance (Cambridge, MA), a clinical stage pharmaceutical company developing a norepinephrine, dopamine and serotonin triple uptake inhibitor to treat ADHD, closed a $7M Series A financing. Participants include Novartis Venture Fund and H&Q Life Sciences Investors.

Rib-X Pharmaceuticals (New Haven, CT), a clinical-stage pharmaceutical company developing next-generation antibiotics, closed an $18.7M Series B financing. Participants include Vatera Healthcare Partners, Warburg Pincus, ABS Ventures and Vox Equity Partners.

TransMedics (Andover, MA) a commercial-stage medical device company focused on organ preservation technologies for transplants, closed a $36M Series E financing. Participants include Abrams Capital, Flagship Ventures, Hercules Technology Growth Capital and Kleiner Perkins Caufield & Byers.

Rhythm Pharmaceuticals (Boston, MA), a clinical-stage biotechnology company focused on peptide therapeutics for metabolic disorders, closed an $8M Series B financings, bringing the total round to $33M. Participants include Pfizer Ventures, MPM Capital, New Enterprise Associates, Third Rock Ventures and Ipsen Ventures. Collective IP | The World’s Largest Technology Transfer Office Marketplace Providing Unrivaled Comprehensive [...]

Visterra (Cambridge, MA), a preclinical-stage biotechnology company focused on seasonal and pandemic influenza, closed a $13M Series A financing, bringing the total round to $26M. Participants include The Bill & Melinda Gates Foundation, Omega Funds, Polaris Venture Partners, Flagship Ventures and Lux Capital. Collective IP | The World’s Largest Technology Transfer Office Marketplace Providing Unrivaled [...]

Metamark Genetics (Cambridge, MA), a preclinical-stage molecular diagnostics company focused on cancer, closed a $13M Series B financing. Participants were not identified. Collective IP | The World’s Largest Technology Transfer Office Marketplace Providing Unrivaled Comprehensive and Accurate Access to Humankinds Most Valuable and Transformative Assets Receive Collective IP Account Access HERE

Gliknik (Baltimore, MD), a clinical-stage biotechnology company focused on treatments for cancer and autoimmune diseases, closed a $4.9M Series B financing. Participants include Baxter Ventures. Collective IP | The Most Comprehensive and Accurate View of Global Innovation and Organization of the International Technology Transfer Office Ecosystem Request Collective IP Account Access HERE

Promedior (Malvern, PA), a clinical-stage biotechnology company focused on Age-Related Macular Degeneration, closed a $3M Series D financing, bringing the total round to $24.5M. Participants include Shire Strategic Investment Group, Fibrotec Ventures, Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, Forbion Capital Partners and Easton Capital Investment Group. Collective IP | The Most Comprehensive and Accurate [...]

Genocea Biosciences (Cambridge, MA), a clinical-stage biotechnology company focused on therapeutic and prophylactic vaccines for infectious diseases, closed a $30M Series C financing. Participants include Bill & Melinda Gates Foundation, Central Valley Fund, Johnson & Johnson Development Corp., Skyline Ventures, MP Healthcare Venture Management, Polaris Venture Partners, Lux Capital Management, SR One, Cycad Group, Auriga [...]

Cibiem (New York, NY), a development-stage medical device company focused on sympathetic nervous system-mediated diseases, closed a $10M Series A financing. Participants include SV Life Sciences and Third Rock Ventures. Collective IP | The Most Comprehensive and Accurate View of Global Innovation and Organization of the International Technology Transfer Office Ecosystem Request Collective IP Account [...]

Healthrageous (Boston, MA), a commercial-stage Health IT provider of self-management solutions, closed a $6.5M Series B financing. Participants include North Bridge Venture Partners, Egan-Managed Capital and Long River Ventures. Collective IP | The Most Comprehensive and Accurate View of Global Innovation and Organization of the International Technology Transfer Office Ecosystem Request Collective IP Account Access HERE

« Previous Entries  Next Page »

to top of page...